Michael Quigley

Michael Quigley

Gilead Sciences Inc. - California / United States
Others
AD Scientific Index ID: 4387596
-
person_outline Michael Quigley's MOST POPULAR ARTICLES
1-) Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cellsMJ Selby, JJ Engelhardt, M Quigley, KA Henning, T Chen, M Srinivasan, ...Cancer immunology research 1 (1), 32-42, 20137942013
2-) Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATFM Quigley, F Pereyra, B Nilsson, F Porichis, C Fonseca, Q Eichbaum, ...Nature medicine 16 (10), 1147-1151, 20105042010
3-) VISTA is an acidic pH-selective ligand for PSGL-1RJ Johnston, LJ Su, J Pinckney, D Critton, E Boyer, A Krishnakumar, ...Nature 574 (7779), 565-570, 20192322019
4-) Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicologyMJ Selby, JJ Engelhardt, RJ Johnston, LS Lu, M Han, K Thudium, D Yao, ...PloS one 11 (9), e0161779, 20162462016
5-) PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantationWJ Norde, F Maas, W Hobo, A Korman, M Quigley, MGD Kester, ...Cancer research 71 (15), 5111-5122, 20111842011